Study on the Level of Neuromuscular Blockade

NACompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

July 31, 2019

Study Completion Date

December 31, 2019

Conditions
Neuromuscular Blockade
Interventions
DRUG

A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).

50 patients undergoing laparoscopic gastrectomy surgery will be allocated to group D. A continuous intravenous infusion of 0.5-0.6 mg/kg/h rocuronium to keep the target neuromuscular blockade (PTC = 1-2).

DRUG

A continuous intravenous infusion of 0.2-0.3 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (TOF = 1-2).

33 patients undergoing laparoscopic gastrectomy surgery will be allocated to group M. A continuous intravenous infusion of 0.2-0.3 mg/kg/h rocuronium to keep the target neuromuscular blockade (TOF = 1-2).

Trial Locations (1)

210000

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

Wu Jieping Medical Foundation

OTHER

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT03782233 - Study on the Level of Neuromuscular Blockade | Biotech Hunter | Biotech Hunter